Charles Schwab Investment Management Inc. Sells 6,220 Shares of Theravance Biopharma, Inc. $TBPH

Charles Schwab Investment Management Inc. lessened its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 2.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 287,716 shares of the biopharmaceutical company’s stock after selling 6,220 shares during the period. Charles Schwab Investment Management Inc. owned 0.58% of Theravance Biopharma worth $2,569,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Aquatic Capital Management LLC bought a new position in Theravance Biopharma during the fourth quarter worth $25,000. GAMMA Investing LLC increased its stake in Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 3,281 shares in the last quarter. R Squared Ltd increased its stake in Theravance Biopharma by 636.6% in the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 10,822 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Theravance Biopharma by 142.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,670 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 7,452 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in Theravance Biopharma in the fourth quarter valued at $119,000. Institutional investors own 99.10% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 24,000 shares of the business’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president directly owned 336,918 shares in the company, valued at approximately $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 44,000 shares of company stock worth $491,800 in the last 90 days. 6.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TBPH shares. BTIG Research lifted their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, June 27th. Jones Trading raised shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price target for the company in a research note on Tuesday, June 17th. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Finally, Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Strong Buy” and a consensus target price of $21.33.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $13.88 on Friday. Theravance Biopharma, Inc. has a fifty-two week low of $7.88 and a fifty-two week high of $14.30. The stock has a market cap of $699.00 million, a PE ratio of 57.83 and a beta of 0.01. The firm’s 50-day simple moving average is $11.80 and its 200 day simple moving average is $10.29.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.